Sarah E. Hempstead
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sarah E. Hempstead has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Albert Faro
Cystic Fibrosis Foundation, Bethesda, MD, USA
3 shared publications - Patrick A. Flume
Medical University of South Carolina, Charleston, South Carolina, USA
3 shared publications - A. Whitney Brown
Cystic Fibrosis Foundation, Bethesda, MD, USA
2 shared publications - Alexander Philbrick
Canning Thoracic Institute, Northwestern Medicine, Chicago, Illinois, USA
2 shared publications - Cade Hovater
Emory School of Medicine, Randall Rollins Bldg, 5th Floor, 1518 Clifton Rd NE, Atlanta, GA 30322, USA
2 shared publications - Daniel Peckham
Leeds Institute of Medical Research, University of Leeds, Leeds, UK
2 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (11)
Research priorities and knowledge gaps in understanding hepatobiliary disease in cystic fibrosis
Was not provided for this article.
- 14 October 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (11)
Open AccessResearch priorities and knowledge gaps in understanding hepatobiliary disease in cystic fibrosis
Was not provided for this article.
- Top Cited PapersOpen Access
- 2 April 2025
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 11 (2) , 24
Cystic Fibrosis Newborn Screening: A Systematic Review-Driven Consensus Guideline from the United States Cystic Fibrosis Foundation
Newborn screening for cystic fibrosis (CF) has been universal in the US since 2010; however, there is significant variation among newborn screening algorithms. Systematic reviews were used to develop seven recommendations for newborn screening program practices to improve timeliness, sensitivity, and equity in diagnosing infants with CF: (1) The CF Foundation recommends the use of a floating immunoreactive trypsinogen (IRT) cutoff over a fixed IRT cutoff; (2) The CF Foundation recommends using a very high IRT referral strategy in CF newborn screening programs whose variant panel does not include all CF-causing variants in CFTR2 or does not have a variant panel that achieves at least 95% sensitivity in all ancestral groups within the state; (3) The CF Foundation recommends that CF newborn screening algorithms should not limit CFTR variant detection to the F508del variant or variants included in the American College of Medical Genetics-23 panel; (4) The CF Foundation recommends that CF newborn screening programs screen for all CF-causing CFTR variants in CFTR2; (5) The CF Foundation recommends conducting CFTR variant screening twice weekly or more frequently as resources allow; (6) The CF Foundation recommends the inclusion of a CFTR sequencing tier following IRT and CFTR variant panel testing to improve the specificity and positive predictive value of CF newborn screening; (7) The CF Foundation recommends that both the primary care provider and the CF specialist be notified of abnormal newborn screening results. Through implementation, it is anticipated that these recommendations will result in improved sensitivity, equity, and timeliness of CF newborn screening, leading to improved health outcomes for all individuals diagnosed with CF following newborn screening and a decreased burden on families.
- 2 April 2025
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 11 (2) , 24
Top Cited PapersOpen AccessCystic Fibrosis Newborn Screening: A Systematic Review-Driven Consensus Guideline from the United States Cystic Fibrosis Foundation
Newborn screening for cystic fibrosis (CF) has been universal in the US since 2010; however, there is significant variation among newborn screening algorithms. Systematic reviews were used to develop seven recommendations for newborn screening program practices to improve timeliness, sensitivity, and equity in diagnosing infants with CF: (1) The CF Foundation recommends the use of a floating immunoreactive trypsinogen (IRT) cutoff over a fixed IRT cutoff; (2) The CF Foundation recommends using a very high IRT referral strategy in CF newborn screening programs whose variant panel does not include all CF-causing variants in CFTR2 or does not have a variant panel that achieves at least 95% sensitivity in all ancestral groups within the state; (3) The CF Foundation recommends that CF newborn screening algorithms should not limit CFTR variant detection to the F508del variant or variants included in the American College of Medical Genetics-23 panel; (4) The CF Foundation recommends that CF newborn screening programs screen for all CF-causing CFTR variants in CFTR2; (5) The CF Foundation recommends conducting CFTR variant screening twice weekly or more frequently as resources allow; (6) The CF Foundation recommends the inclusion of a CFTR sequencing tier following IRT and CFTR variant panel testing to improve the specificity and positive predictive value of CF newborn screening; (7) The CF Foundation recommends that both the primary care provider and the CF specialist be notified of abnormal newborn screening results. Through implementation, it is anticipated that these recommendations will result in improved sensitivity, equity, and timeliness of CF newborn screening, leading to improved health outcomes for all individuals diagnosed with CF following newborn screening and a decreased burden on families.
- 25 September 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (6) , 1066-1071
Adapting the cystic fibrosis care model: Perspectives from people with CF, caregivers, and members of CF care teams
- 25 September 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (6) , 1066-1071
Adapting the cystic fibrosis care model: Perspectives from people with CF, caregivers, and members of CF care teams
- Open Access
- 25 September 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (6) , 1045-1054
Cystic fibrosis foundation position paper: Redefining the cystic fibrosis care team
- 25 September 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (6) , 1045-1054
Open AccessCystic fibrosis foundation position paper: Redefining the cystic fibrosis care team
- Top Cited PapersOpen Access
- 26 October 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 79 (5) , 1220-1238
Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations
Background and Aims Cystic fibrosis (CF) may cause a spectrum of hepatobiliary complications, including portal hypertension, multilobular cirrhosis, and liver failure. Current guidelines on the detection and monitoring of hepatobiliary complications in CF were published in 1999. The CF Foundation assembled a committee to evaluate research advances and formulate revised guidelines for CF-associated liver disease. Approach A committee of hepatologists, gastroenterologists, pulmonologists, pharmacist, nurse, dietitian, individual with CF, and parent of a child with CF devised “population, intervention, comparison, and outcome” (PICO) questions regarding hepatobiliary disease in CF. PubMed literature searches were performed for each PICO question. Recommendations were voted on with 80% agreement required to approve a recommendation. Public comment on initial recommendations was solicited prior to formulation of final recommendations. Results 31 PICO questions were assembled, 6,401 manuscripts were title screened for relevance, with 1,053 manuscripts undergoing detailed full text review. Seven recommendations were approved for screening, 13 for monitoring of existing disease, and 14 for treatment of CF-associated hepatobiliary involvement or advanced liver disease. One recommendation on liver biopsy did not meet the 80% threshold. One recommendation on screening ultrasound was revised and re-voted on. Conclusions Through a multidisciplinary committee and public engagement, we have assembled updated recommendations and guidance on screening, monitoring and treatment of CF-associated hepatobiliary involvement and advanced liver disease. While research gaps remain, we anticipate that these recommendations will lead to improvements in CF outcomes through earlier detection and increased evidence-based approaches to monitoring and treatment. Export
- 26 October 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 79 (5) , 1220-1238
Top Cited PapersOpen AccessCystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations
Background and Aims Cystic fibrosis (CF) may cause a spectrum of hepatobiliary complications, including portal hypertension, multilobular cirrhosis, and liver failure. Current guidelines on the detection and monitoring of hepatobiliary complications in CF were published in 1999. The CF Foundation assembled a committee to evaluate research advances and formulate revised guidelines for CF-associated liver disease. Approach A committee of hepatologists, gastroenterologists, pulmonologists, pharmacist, nurse, dietitian, individual with CF, and parent of a child with CF devised “population, intervention, comparison, and outcome” (PICO) questions regarding hepatobiliary disease in CF. PubMed literature searches were performed for each PICO question. Recommendations were voted on with 80% agreement required to approve a recommendation. Public comment on initial recommendations was solicited prior to formulation of final recommendations. Results 31 PICO questions were assembled, 6,401 manuscripts were title screened for relevance, with 1,053 manuscripts undergoing detailed full text review. Seven recommendations were approved for screening, 13 for monitoring of existing disease, and 14 for treatment of CF-associated hepatobiliary involvement or advanced liver disease. One recommendation on liver biopsy did not meet the 80% threshold. One recommendation on screening ultrasound was revised and re-voted on. Conclusions Through a multidisciplinary committee and public engagement, we have assembled updated recommendations and guidance on screening, monitoring and treatment of CF-associated hepatobiliary involvement and advanced liver disease. While research gaps remain, we anticipate that these recommendations will lead to improvements in CF outcomes through earlier detection and increased evidence-based approaches to monitoring and treatment. Export
- 30 May 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (6) , 1100-1103
Clinician perspectives on barriers and solutions to symptom management in cystic fibrosis
- 30 May 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (6) , 1100-1103
Clinician perspectives on barriers and solutions to symptom management in cystic fibrosis
- Open Access
- 23 May 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (5) , 788-795
Nutritional considerations for a new era: A CF foundation position paper
- 23 May 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (5) , 788-795
Open AccessNutritional considerations for a new era: A CF foundation position paper
- Open Access
- 5 March 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (3) , 374-380
Position paper: Models of post-transplant care for individuals with cystic fibrosis
- 5 March 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (3) , 374-380
Open AccessPosition paper: Models of post-transplant care for individuals with cystic fibrosis
- 1 May 2021
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 20 (3) , 407-412
Antimicrobial resistance: Concerns of healthcare providers and people with CF
- 1 May 2021
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 20 (3) , 407-412
Antimicrobial resistance: Concerns of healthcare providers and people with CF
- Open Access
- 13 July 2020
- Published by JMIR Publications Inc. in Journal of Participatory Medicine
- Vol. 12 (3) , e17875
Patient and Family Participation in Clinical Guidelines Development: The Cystic Fibrosis Foundation Experience
Patient and family participation in guideline development is neither standardized nor uniformly accepted in the guideline development community, despite the 2011 Institute of Medicine’s Guidelines We Can Trust and the Guideline International Network’s GIN-Public Toolkit recommendations. The Cystic Fibrosis Foundation has included patients and/or family members directly in guideline development since 2004. Over time, various strategies for increasing patient and family member participation have been implemented. Surveys of recent patient/family and clinical guidelines committee members have shown that inclusion of individuals with cystic fibrosis and their family members on guidelines committees has provided insight otherwise invisible to clinicians.
- 13 July 2020
- Published by JMIR Publications Inc. in Journal of Participatory Medicine
- Vol. 12 (3) , e17875
Open AccessPatient and Family Participation in Clinical Guidelines Development: The Cystic Fibrosis Foundation Experience
Patient and family participation in guideline development is neither standardized nor uniformly accepted in the guideline development community, despite the 2011 Institute of Medicine’s Guidelines We Can Trust and the Guideline International Network’s GIN-Public Toolkit recommendations. The Cystic Fibrosis Foundation has included patients and/or family members directly in guideline development since 2004. Over time, various strategies for increasing patient and family member participation have been implemented. Surveys of recent patient/family and clinical guidelines committee members have shown that inclusion of individuals with cystic fibrosis and their family members on guidelines committees has provided insight otherwise invisible to clinicians.